Treatment status of HIV patients in Denmark in 2010 by origin and route of HIV transmission.

<div><p>Successful management is defined as viral load <500 copies/mL or non-eligibility to HAART, but monitoring of CD4 within 13 months.</p> <p>DK: Denmark, HAART: highly active antiretroviral therapy, IDU: injection drug user, S: Sweden, VL: viral load.</p></div

Treatment status of patients in the Swedish-Danish HIV cohort in the period 1995-2010.

<p>The panels represent all patients in the cohort (A) and stratified by origin (B: Swedish/Danish origin and C: Immigrants) and by route of HIV transmission (D: MSM, E: Heterosexuals and F: Injection drug users).</p

Basic characteristics for Danish born HIV-infected individuals and comparison cohort individuals.

<p><b>Abbreviations:</b> IQR: Interquartile range; IR: Incidence Rate; 95% CI: 95% Confidence Interval; PYR: Person-years; MSM: men who have sex with men; DM: Diabetes Mellitus; HAART: Highly Active Antiretroviral Therapy.</p

Mortality rate ratio (MRR) of HIV-infected individuals initiating HAART after 1 January 1998 with a VL <50copies/ml within 180 days of HAART initiation, with no censoring due to virological failure, comparing time on statin with time not on statin.

<p><b>Abbreviations</b>: MRM: Mortality Rate Ratio; 95% CI: 95% Confidence Interval; PYR: Person years of follow-up; MSM: men who have sex with men; HAART: Highly Active Antiretroviral Therapy.</p>*<p><b>Adjustment 1</b>: Adjusted for age (treated as time-updated variables split at 30, 40, 50, 60,70), gender, race, HIV transmission group, CD4 cell count at HAART initiation (<50, 50–200, >200 cells/µl), HIV VL at HAART initiation (log10 VL), total cholesterol (<5, 5–8, >8, missing values), year of HAART initiation (<2004 vs. > = 2004), ART prior to HAART, AIDS defining illness prior to HAART initiation, Viral hepatitis C co-infection.</p>*<p><b>Adjustment 2:</b> Adjusted for variables as in model 1+ comorbidity and the clinically important interaction between comorbidity and statin use/non-use, The MRRs are therefore presented both before and after development of a comorbid condition. Comorbidity is defined as the first of the following comorbid conditions: coronary artery disease, cerebrovascular disease, peripheral artery disease, chronic kidney disease and a redeemed prescription of an antidiabetic drug and introduced as a time-updated variable.</p

Risk of diabetes mellitus (DM) in Danish born HIV-infected individuals compared to Danish born comparison cohort individuals.

<p><b>Abbreviations:</b> IRR: Incidence rate ratio; 95% CI: Confidence Interval; PYR: Person-years; HAART: Highly Active Antiretroviral Therapy.</p>*<p>Adjusted for age (split at 30, 35, 40, 45, 50, 55, 60 and 65), gender and calendar time (split at 3, 5, 8 and 11 years after January 1, 1996).</p>**<p>Analysed separately according to split in calendar time (split at 3 years after January 1, 1996) and adjusted for age (split at 30, 35, 40, 45, 50, 55, 60, and 65) and gender. For time periods after 31 December1998 the analysis were further adjusted for calendar time (split at 5, 8, 11 years after January 1, 1996).</p

Cumulative incidence of diabetes mellitus in Danish born HIV-infected individuals compared to a Danish born comparison cohort.

<p>(Index date: the latest of 1 January 1996 or date of HIV diagnosis).</p

Impact of specific antiretroviral drugs on risk of diabetes mellitus (DM) in Danish born HIV-infected individuals on HAART.

<p><b>Abbreviations:</b> IRR: Incidence rate ratio; 95% CI: Confidence Interval; PYR: Person-years; Ref: Reference group ∼ HIV-infected individuals on HAART not exposed to the investigated antiretroviral drug.</p>*<p>Adjusted for age (split at 30, 40, 50 and 60), gender, calendar time (split at 3, 5, 8 and 11 years after January 1, 1996), Hepatitis C infection or intravenous drug abuse, and CD4 cell count (split at date of CD4 cell count >200 cells/µL after start of HAART).</p

Characteristics of HIV<b>-</b>infected individuals initiating HAART after 1 January 1998 with a VL < 50 copies/ml within 180 days of HAART initiation.

<p><b>Abbreviations:</b> IQR: Interquartile range; MR: Mortality Rate; 95% CI: 95% Confidence Interval; MSM: men who have sex with men; HAART: Highly Active Antiretroviral Therapy; VL: Viral Load.</p>*<p>The column “Individuals with Non-STATIN time” includes data on all patients who were not on statin treatment at study entry, and the column “Individuals with time on a STATIN” includes data on all patients who during observation time were treated with statin. Some patients were therefore included in both columns why the total number adds up to more than 100%.</p><p>For conversion from the SI unit mmol/L to mg/dL: (mg/dL cholesterol  =  mmol/L * 38.6) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052828#pone.0052828-EuropeanAssociationforCardiovascularPrevention1" target="_blank">[33]</a>.</p

Mortality rate ratio (MRR) of HIV-infected individuals initiating HAART after 1 January 1998 with a VL <50 copies/ml within 180 days of HAART initiation with censoring of individuals with virological failure (VL >500copies/ml) comparing time on statin with time not on statin.

<p><b>Abbreviations:</b> MRM: Mortality Rate Ratio; 95% CI: 95% Confidence Interval; PYR: Person years of follow-up; MSM: men who have sex with men; HAART: Highly Active Antiretroviral Therapy.</p>*<p><b>Adjustment 1:</b> Adjusted for age (treated as time-updated variables split at 30, 40, 50, 60,70), gender, race, HIV transmission group, CD4 cell count at HAART initiation (<50, 50–200, >200 cells/µl), HIV VL at HAART initiation (log₁₀ VL), total cholesterol (<5, 5–8, >8, missing values), year of HAART initiation (<2004 vs. > = 2004), ART prior to HAART, AIDS defining illness prior to HAART initiation, Viral hepatitis C co-infection.</p>*<p><b>Adjustment 2:</b> Adjusted for variables as in model 1 + comorbidity and the clinically important interaction between comorbidity and statin use/non-use, The MRRs are therefore presented both before and after development of a comorbid condition. Comorbidity is defined as the first of the following comorbid conditions: coronary artery disease, cerebrovascular disease, peripheral artery disease, chronic kidney disease and a redeemed prescription of an antidiabetic drug and introduced as a time-updated variable.</p

Summary of the study design.

<p>Summary of the study design.</p